Passing of Genmab A/S’ Annual General Meeting
13 März 2024 - 4:13PM
Passing of Genmab A/S’ Annual General Meeting
Company Announcement
- At Genmab A/S’ Annual General Meeting held
today March 13, 2024, the Annual Report for
2023 was approved
- Discharge was given to the Board of Directors and the
Executive Management and the year’s profit was
carried forward
- The 2023 Compensation Report
was approved
- Six members of the Board of Directors
were re-elected
- Deloitte was elected as the new auditor of
the Company
- The proposal from the Board of Directors on
the Board of Directors' remuneration for 2024, the proposal to
adopt an indemnification scheme, the proposal on a new Remuneration
Policy, the proposal to acquire treasury shares and the proposals
to amend Article 4A, Article 5, Article 5A and Article 5B and to
enter a new Article 14 in the Articles of Association
were adopted
COPENHAGEN, Denmark; March
13, 2024 – Genmab
A/S (Nasdaq: GMAB) held its Annual
General Meeting, today at the Copenhagen Marriott Hotel,
Copenhagen, Denmark. At the meeting, Deirdre P.
Connelly, Chair of the Board of Directors gave – on behalf of the
Board of Directors – a report on the Company’s activities during
the past year. Chief Executive Officer Dr. Jan van de Winkel
presented the Company’s plans for 2024, and Chief Financial Officer
Mr. Anthony Pagano presented the Annual Report for 2023 endorsed by
the previous auditors, PricewaterhouseCoopers. The report was
approved, and discharge was given to the Board of Directors and the
Executive Management.
It was decided that the year’s profit of DKK 4,352 million be
carried forward by transfer to retained earnings, as stated in the
Annual Report.
The 2023 Compensation Report was approved.
Ms. Deirdre P. Connelly, Ms. Pernille Erenbjerg, Mr. Rolf
Hoffmann, Dr. Paolo Paoletti, Dr. Anders Gersel Pedersen and Ms.
Elizabeth O’Farrell were re-elected to the Board of Directors for a
one-year period.
Deloitte Statsautoriseret Revisionspartnerselskab was elected as
the Company’s new auditor.
The General Meeting adopted the proposals from the Board of
Directors, as follows:
- The proposal to adopt the Board of Directors’ remuneration for
2024.
- The proposal to adopt a scheme for indemnification of members
of the Board of Directors.
- The proposal to adopt a new Article 14 of the Articles of
Association including the indemnification scheme in the Articles of
Associations.
- The proposals to adopt a new Remuneration Policy for the Board
of Directors and the Executive Management.
- The proposal to replace the authorizations in Article 4A (to
issue new shares) and Article 5A (to issue convertible debt
instruments) of the Articles of Association with new authorizations
to the Board of Directors to issue new shares and convertible debt
instruments respectively, which collectively can be utilized to
increase the share capital of the Company up to a total nominal
amount of DKK 6,600,000 for a period ending on March 12, 2029 and
thereby to amend Articles 4A, 5A and 5B.
- The proposal to amend Article 5 of the Articles of Association
so that the Board of Directors is authorized to issue additional
warrants that give the right to subscribe up to nominally DKK
750,000 shares in the Company.
- The proposal to authorize the Board of Directors to mandate the
Company to acquire treasury shares up to the total nominal amount
of DKK 3,500,000.
About Genmab Genmab is an international
biotechnology company with a core purpose guiding its unstoppable
team to strive towards improving the lives of patients through
innovative and differentiated antibody therapeutics. For 25 years,
its passionate, innovative and collaborative team has invented
next-generation antibody technology platforms and leveraged
translational, quantitative, and data sciences, resulting in a
proprietary pipeline including bispecific T-cell engagers,
next-generation immune checkpoint modulators, effector function
enhanced antibodies, and antibody-drug conjugates. To help develop
and deliver novel antibody therapies to patients, Genmab has formed
20+ strategic partnerships with biotechnology and pharmaceutical
companies. By 2030, Genmab’s vision is to transform the lives of
people with cancer and other serious diseases with
knock-your-socks-off (KYSO®) antibody medicines.
Established in 1999, Genmab is headquartered in Copenhagen,
Denmark with locations in Utrecht, the Netherlands, Princeton, New
Jersey, U.S., and Tokyo, Japan. For more information, please
visit Genmab.com and follow us on LinkedIn and
X.
Contact:
Marisol Peron, Senior Vice President, Global Communications &
Corporate AffairsT: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor RelationsT: +45
3377 9558; E: acn@genmab.com
This Company Announcement contains forward looking statements.
The words “believe,” “expect,” “anticipate,” “intend” and “plan”
and similar expressions identify forward looking statements. Actual
results or performance may differ materially from any future
results or performance expressed or implied by such statements. The
important factors that could cause our actual results or
performance to differ materially include, among others, risks
associated with preclinical and clinical development of products,
uncertainties related to the outcome and conduct of clinical trials
including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products or technologies obsolete, and other factors. For a further
discussion of these risks, please refer to the risk management
sections in Genmab’s most recent financial reports, which are
available on www.genmab.com and the risk factors included in
Genmab’s most recent Annual Report on Form 20-F and other filings
with the U.S. Securities and Exchange Commission (SEC), which are
available at www.sec.gov. Genmab does not undertake any obligation
to update or revise forward looking statements in this Company
Announcement nor to confirm such statements to reflect subsequent
events or circumstances after the date made or in relation to
actual results, unless required by law. Genmab A/S and/or its
subsidiaries own the following trademarks: Genmab®; the Y-shaped
Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®;
HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®.
Company Announcement no. 19 CVR no. 2102 3884 LEI Code
529900MTJPDPE4MHJ122
Genmab A/SCarl Jacobsens Vej 302500 Valby Denmark
- 130324_CA19_Passing of AGM
Genmab AS (TG:GE9)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Genmab AS (TG:GE9)
Historical Stock Chart
Von Jun 2023 bis Jun 2024